Teva and Samsung Bioepis will work together to sell two FDA-approved biosimilars in the U.S.

Nov 3, 2026, 7:13 AM ETDealRead the original at globenewswire.com

Good for TEVA

Teva gains U.S. selling rights to 2 FDA-approved biosimilars, expanding its drug lineup. The rights transfer in stages, the deal still needs to close, and Samsung keeps manufacturing and regulatory oversight, but the added products favor Teva.

TEVA · Teva Pharmaceutical Industries Ltd.

AI read · Good for TEVA

The AI's read

The added products give Teva more medicines to sell in the U.S. Samsung Bioepis will keep making the drugs and handling regulatory work, so Teva is focused on selling them. One product's rights transfer at closing, and the other's are scheduled for Q3 2027. The deal still needs to close by the end of 2026 under customary conditions. Those timing limits temper the benefit, but added sales rights make the news favorable for Teva.

Get alerts for TEVA

Follow Teva Pharmaceutical Industries Ltd. (TEVA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for TEVA

Free on the App Store and Google Play, or on the web.